Alpha-1 Antitrypsin Deficiency

• Genetic basis and protein misfolding: The AAT gene contains functional variants designated by the Pi (protease inhibitor) typing system. The normal allele is designated M (medium), while disease-causing alleles include S (slow) and Z (very slow). The Z allele results from two critical amino acid substitutions (Glu342Lys and Lys391Met) that promote polymerization and misfolding of the AAT protein in the endoplasmic reticulum (ER) of hepatocytes. The most clinically severe form is PiZZ genotype (Z/Z homozygous), where only 10-15% of normal serum AAT levels are achieved (typically <50 mg/dL; normal >150 mg/dL). The S allele results in intermediate disease expression. Heterozygous states (PiMZ, PiSZ) result in intermediate AAT levels but rarely cause significant organ disease unless additional risk factors like smoking are present. The polymerized AAT protein accumulates within hepatocyte ER as inclusions, contributing to liver pathology independent of systemic deficiency.

• Pulmonary elastase-antiprotease imbalance: In the lungs, AAT is the primary physiologic inhibitor of neutrophil elastase, a serine protease released during inflammatory cell activation. AAT achieves high concentrations in lung epithelial lining fluid through direct hepatic synthesis and local production by alveolar macrophages. With severe AAT deficiency (PiZZ phenotype), lung AAT levels fall to <10% of normal. This allows unopposed neutrophil elastase activity, which degrades structural components of the extracellular matrix including elastin, collagen, and fibronectin. The pathophysiologic cascade proceeds as: (1) neutrophil recruitment triggered by cigarette smoke or other irritants; (2) elastase release into the alveolar space; (3) unchecked proteolytic degradation of lung parenchyma; (4) progressive alveolar destruction manifesting as emphysema. The destructive process is particularly severe in the lower lobes and basilar segments, distinguishing AAT-associated emphysema from typical smoking-related emphysema (which predominates in the upper lobes). Additionally, oxidative stress from cigarette smoke inactivates the remaining AAT through oxidation of a critical methionine residue at the protease binding site, further exacerbating the protease-antiprotease imbalance even in heterozygous individuals who smoke.

• Hepatic disease pathophysiology: The Z-variant AAT protein misfolds within hepatocyte ER, forming polymeric aggregates that accumulate as periodic acid-Schiff (PAS)-positive, diastase-resistant intracellular inclusions. This ER retention activates the unfolded protein response (UPR) and promotes hepatocyte apoptosis, leading to chronic inflammation and progressive fibrosis. Neonates with PiZZ genotype frequently develop neonatal hepatitis and cholestasis (5-10% of affected newborns), manifesting as jaundice persisting beyond 2 weeks, direct hyperbilirubinemia, hepatomegaly, and elevated transaminases. The mechanism involves accumulation of polymerized AAT and subsequent ER stress, distinct from the protease-antiprotease mechanism operating in lung disease. In children and adults, chronic ER-mediated hepatocyte injury can progress to cirrhosis through stages of chronic hepatitis, fibrosis, and eventually decompensated liver disease, though progression is more indolent than in lung disease. The risk of developing cirrhosis by age 50 in PiZZ individuals is approximately 10-15%, with male gender and concurrent hepatitis C infection increasing risk substantially. Intriguingly, some individuals with severe AAT deficiency never develop significant liver disease, suggesting modifier genes and environmental factors influence hepatic outcomes.

• Systemic and inflammatory mechanisms: Beyond the protease-antiprotease imbalance, AAT possesses anti-inflammatory properties through multiple mechanisms: inhibition of tumor necrosis factor-alpha (TNF-α) production by macrophages, reduction of neutrophil migration through chemokine modulation, and direct anti-apoptotic effects on epithelial cells. With severe deficiency, this anti-inflammatory capacity is lost, leading to amplified inflammatory responses to modest stimuli. Additionally, AAT has been shown to inhibit pancreatic elastase and other serine proteases, providing a mechanistic basis for the rare association with vasculitis and panniculitis in severely deficient patients.

• Genetic factors—Pi typing system: The severity of AAT deficiency is determined by the Pi phenotype/genotype. PiZZ homozygotes represent the classic severe form with serum AAT levels typically 10-57 mg/dL (severe deficiency threshold is <57 mg/dL or <11 μM). PiSZ compound heterozygotes have intermediate deficiency (40-80 mg/dL) with disease risk intermediate between PiZZ and normal individuals. PiMZ heterozygotes have mildly reduced levels (80-110 mg/dL) and rarely develop clinically significant disease. Other rare variants include PiMM (normal), PiMS, PiSS (mild deficiency), and rare null variants (complete absence of serum AAT, most severe form). The Pi typing is based on isoelectric focusing of serum proteins, identifying M, S, and Z alleles by their isoelectric points. Understanding that individuals presenting with "early-onset COPD" (before age 45), basilar-predominant emphysema on imaging, or family history of emphysema should be screened regardless of smoking history, as heterozygotes are at risk with additional triggers.

• Cigarette smoking—critical amplifying factor: Smoking is the single most impactful acquired risk factor in AAT deficiency. Smokers with PiZZ genotype typically develop symptomatic COPD 15-20 years earlier than non-smokers with the same genotype (average age of onset 40-50 years in smokers vs. 50-70 years in non-smokers). The mechanism involves: (1) direct oxidative inactivation of circulating and lung-resident AAT; (2) neutrophil recruitment and elastase release triggered by smoke irritation; (3) additive inflammatory burden. Even heterozygous PiMZ individuals who smoke have increased risk of COPD compared to non-smoking PiMZ individuals. Notably, the risk in non-smoking PiZZ individuals is substantially lower than in smokers; some non-smokers remain asymptomatic throughout life. This gene-environment interaction is critical for counseling and risk stratification.

• Environmental exposures and occupational factors: Chronic occupational exposures (dust, fumes, gases) in industries such as mining, welding, and chemical manufacturing may accelerate lung disease in deficient individuals through additional neutrophil recruitment and elastase burden. Occupational exposure in the absence of smoking carries lesser risk but should inform clinical management.

• Modifying genetic factors: Certain genetic polymorphisms in other genes influence phenotypic expression of AAT deficiency. Variations in matrix metalloproteinase genes (MMP-9), transforming growth factor-beta (TGF-β), and tumor necrosis factor (TNF) have been associated with differences in lung disease severity and progression rates among PiZZ individuals with similar exposure histories. Additionally, heterozygosity for other genetic conditions affecting protease activity (e.g., certain MMP variants) may modulate disease expression.

• Concurrent hepatotropic viral infections: Individuals with AAT deficiency infected with hepatitis B or C virus demonstrate markedly accelerated progression to cirrhosis, likely due to additive hepatocyte injury from viral replication plus ER stress from polymerized AAT accumulation. This is a critical consideration in management, as these individuals should be prioritized for antiviral therapy and hepatological monitoring.

• Age and disease progression factors: While AAT deficiency is congenital, symptoms typically manifest in adulthood (fourth to sixth decade in non-smokers, second to fourth decade in smokers), suggesting threshold effects and accumulation of protease-mediated tissue damage over time. The indolent nature in some severely deficient non-smokers suggests protective mechanisms or genetic modifiers that remain incompletely understood.

Pulmonary Manifestations (most common)

• Dyspnea on exertion and progressive airflow limitation: The hallmark pulmonary symptom is dyspnea that progresses insidiously over years to decades, initially noticed only with strenuous exercise (NYHA equivalent Class I-II) but advancing to dyspnea with minimal activity or at rest as emphysematous destruction accumulates. The physiologic basis is progressive loss of elastic recoil and reduction in elastic fibers critical for passive exhalation, leading to air trapping and hyperinflation. In smokers with PiZZ genotype, symptomatic dyspnea typically emerges in the 4th-5th decade; in non-smokers, the 6th-7th decade. Importantly, non-smokers with severe AAT deficiency may remain asymptomatic or minimally symptomatic throughout life, with some individuals discovered incidentally on screening or genetic testing rather than clinical presentation.

• Chronic cough and sputum production: Productive cough is present in a majority of symptomatic patients, often attributed initially to smoking history. In AAT deficiency patients without significant smoking exposure, persistent cough warrants investigation and should prompt AAT screening. The cough reflects chronic airway inflammation and mucus production related to unopposed elastase activity affecting bronchial walls and mucociliary clearance.

• Wheezing and reduced exercise tolerance: Some patients report wheezing, though this finding is less characteristic than in typical COPD from smoking alone, as AAT-related emphysema often presents with a predominance of large airway emphysema rather than small airway obstruction. Exercise tolerance progressively declines, with objective measurements showing reduced FEV1 (forced expiratory volume in 1 second), increased FEV1/FVC ratio reduction, and significant air trapping on pulmonary function testing (elevated total lung capacity and residual volume).

• Recurrent respiratory infections: Some patients report increased susceptibility to respiratory tract infections, though this is not as prominent as in other genetic lung diseases. The mechanism may relate to compromised innate immunity from reduced AAT anti-inflammatory effects and altered local lung defense.

• Hemoptysis (rare): Infrequent but occasionally reported, hemoptysis in AAT deficiency may relate to rupture of small vessels exposed by emphysematous destruction or may signal superimposed conditions requiring exclusion.

Hepatic Manifestations

• Neonatal/infantile cholestasis and hepatitis (PiZZ genotype): In 5-10% of neonates with severe AAT deficiency, cholestasis presents as prolonged jaundice beyond 2 weeks of age, pale stools, dark urine, hepatomegaly, and acholic (pale) stools. Laboratory studies reveal elevated direct (conjugated) bilirubin, elevated alkaline phosphatase, elevated gamma-glutamyl transferase (GGT), and mildly elevated transaminases (ALT/AST). Liver biopsy reveals PAS-positive, diastase-resistant inclusions within hepatocytes. Most neonates recover spontaneously with resolution of cholestasis by 6-12 months, though a subset (1-2%) progress to neonatal sclerosing cholangitis and cirrhosis. The physiologic basis is hepatocyte injury from ER accumulation of polymerized Z-AAT protein, distinct from the lung protease-antiprotease mechanism.

• Childhood liver disease: A proportion of PiZZ children beyond infancy develop insidious hepatitis, presenting as asymptomatic elevation of transaminases discovered on routine screening or evaluation for other causes. Some progress to progressive fibrosis and cirrhosis in childhood or early adulthood, while others remain stable with minimal progression.

• Adult cirrhosis and portal hypertension: In adult PiZZ individuals, the risk of cirrhosis by age 50 is 10-15%, with higher risk in males and those with concurrent hepatitis infection. Cirrhosis may present insidiously with stigmata of chronic liver disease (spider angiomas, palmar erythema, ascites), portal hypertension complications (variceal bleeding), or hepatic encephalopathy. Some adults are discovered to have cirrhosis incidentally on imaging obtained for other indications.

• Hepatocellular carcinoma (HCC) risk: Individuals who develop AAT-associated cirrhosis have increased HCC risk, though absolute rates are lower than in cirrhosis from hepatitis B or C. Surveillance protocols similar to other cirrhosis etiologies are recommended.

Systemic and Rare Manifestations

• Vasculitis (antineutrophil cytoplasmic antibody–negative, typically in severely deficient individuals): Rare cases of necrotizing vasculitis affecting small and medium vessels have been reported in PiZZ individuals, with presentations mimicking granulomatosis with polyangiitis (GPA) but typically without ANCA antibodies. The pathophysiology relates to unopposed proteolytic activity. This association should prompt AAT level checking in vasculitis patients without typical ANCA serology.

• Panniculitis and skin involvement: Rare reports of necrotizing panniculitis in severely deficient individuals, presumed related to unchecked dermal protease activity. This very unusual presentation should heighten suspicion for AAT deficiency.

Physical Examination Findings

• Signs of COPD: In advanced pulmonary disease, examination reveals hyperinflation (barrel chest, decreased cardiac dullness), diminished breath sounds throughout lung fields, prolonged expiration, use of accessory muscles, pursed-lip breathing, and signs of cor pulmonale (prominent jugular venous pulsation, peripheral edema) in advanced stages.

• Liver disease stigmata: In cirrhotic patients, examine for hepatosplenomegaly, ascites (fluid wave, shifting dullness), spider angiomas, palmar erythema, asterixis, jaundice, caput medusae, and other signs of portal hypertension.

• General appearance: Early-stage disease may present with a deceptively well-appearing individual or one with subtle dyspnea; advanced disease shows cachexia and respiratory distress at rest.

Clinical Variants and Presentations

• Non-smoking PiZZ phenotype: Individuals with severe deficiency who never smoked often have minimal pulmonary symptoms, with disease discovered through family screening or incidental findings on imaging obtained for unrelated reasons. Some remain completely asymptomatic.

• Heterozygous phenotypes (PiMZ, PiSZ): These individuals rarely develop clinically significant disease in the absence of smoking or other risk factors, though they may be at modestly increased risk.

• Rapid vs. indolent progression: Among PiZZ smokers, some develop severe COPD and respiratory failure by age 50, while others progress more slowly; this variability likely reflects modifying genetic factors and individual inflammatory responses.

Immediate stabilization (acute exacerbation or decompensation)

• Inhaled short-acting bronchodilators (albuterol ± ipratropium), systemic corticosteroids (prednisone), and antibiotics for exacerbations with increased sputum purulence, per the GOLD report; non-invasive positive pressure ventilation is first-line for acute hypercapnic respiratory failure.
• Controlled supplemental oxygen titrated to a target saturation in the low 90s — high-flow uncontrolled oxygen risks worsening hypercapnia.

First-line therapy (disease-modifying, in order of impact)

• Complete smoking cessation: the single most effective intervention, because smoke oxidizes the methionine at the elastase-binding site and inactivates whatever AAT remains. Combine behavioral support with pharmacotherapy (varenicline, nicotine replacement, bupropion).
• Standard COPD pharmacotherapy per GOLD: long-acting bronchodilators — LAMA (tiotropium) and/or LABA (formoterol), with inhaled corticosteroid added for frequent exacerbators or blood eosinophilia.
• Vaccination and pulmonary rehabilitation: influenza, pneumococcal, COVID-19, pertussis-containing and hepatitis A/B vaccines (ACIP); rehabilitation improves dyspnea and exercise capacity.
• Long-term oxygen therapy for resting hypoxemia, the only therapy proven to reduce mortality in hypoxemic COPD.

Disease-specific escalation

• IV alpha-1 proteinase inhibitor augmentation therapy (pooled human plasma-derived AAT, given weekly): indicated by the ATS/ERS statement and Alpha-1 Foundation for patients with severe deficiency (levels below the protective threshold, ~11 μM) and demonstrated airflow obstruction/emphysema. It raises serum and epithelial lining fluid AAT above the protective threshold and slows CT-measured emphysema progression; it does not reverse existing destruction.

Definitive/surgical management

• Lung transplantation for end-stage emphysema; liver transplantation is curative for AATD liver disease because the recipient assumes the donor's Pi phenotype.
• Lung volume reduction surgery has a limited role — benefit is greatest with upper-lobe heterogeneous disease, whereas AATD emphysema is typically diffuse and basilar.

Contraindicated / not indicated

• Augmentation therapy in liver disease (hepatic injury is from polymer retention, not protease excess), in asymptomatic patients with normal spirometry, in MZ heterozygotes, and in continued smokers who have not attempted cessation.
• IgA-deficient patients with anti-IgA antibodies: risk of anaphylaxis to IgA-containing plasma products.
• Alcohol and other hepatotoxins; treat coexisting hepatitis B/C, which markedly accelerates fibrosis.
• Testing of first-degree relatives and genetic counseling are recommended in all confirmed cases.

Pulmonary complications

• Progressive obstructive respiratory failure: cumulative elastase-mediated alveolar destruction abolishes elastic recoil; signalled by falling FEV1 on serial spirometry, resting hypoxemia, then hypercapnia. Acute hypercapnic decompensation with somnolence or asterixis is an emergency requiring NIV.
• Spontaneous pneumothorax: rupture of subpleural bullae. Sudden pleuritic pain, unilateral absent breath sounds, hyperresonance; tension pneumothorax with hypotension and tracheal deviation is an emergency requiring immediate needle decompression before imaging.
• Cor pulmonale: chronic hypoxic pulmonary vasoconstriction plus capillary bed loss raises pulmonary vascular resistance. Look for elevated JVP, right ventricular heave, hepatomegaly, and peripheral edema.
• Recurrent exacerbations and bronchiectasis: loss of AAT's antiprotease and anti-inflammatory activity impairs airway defense; suggested by chronic purulent sputum and tram-track/signet-ring changes on CT.

Hepatic complications

• Cirrhosis and portal hypertension: retained Z-polymer causes ER stress, hepatocyte apoptosis, and fibrosis. Signalled by thrombocytopenia, splenomegaly, ascites, and a nodular liver on imaging.
• Variceal hemorrhage: hematemesis or melena in a portal hypertensive patient is a life-threatening emergency — resuscitation, octreotide, antibiotic prophylaxis, and urgent endoscopy.
• Hepatic encephalopathy and decompensation: precipitated by infection, bleeding, or constipation; asterixis and altered mentation.
• Hepatocellular carcinoma: cirrhosis is the substrate; AASLD recommends surveillance ultrasound with or without AFP every 6 months in cirrhotic patients. A new arterially enhancing lesion with washout is the signal.
• Neonatal cholestasis progressing to biliary cirrhosis in a minority of PiZZ infants: persistent conjugated hyperbilirubinemia and acholic stools beyond infancy.

Complications of therapy

• Augmentation therapy infusion reactions: fever, urticaria, and rarely anaphylaxis — an emergency treated with epinephrine 0.3 mg IM; highest risk in IgA-deficient patients with anti-IgA antibodies.
• Systemic corticosteroids for exacerbations: hyperglycemia, osteoporosis, and adrenal suppression; inhaled corticosteroids increase pneumonia risk in COPD.
• Transplant complications: acute and chronic rejection (bronchiolitis obliterans syndrome after lung transplant), opportunistic infection (CMV, Pneumocystis, Aspergillus), and calcineurin inhibitor nephrotoxicity.
• Post-surgical prolonged air leak after lung volume reduction in emphysematous, poorly healing tissue.

Rare systemic

• Necrotizing panniculitis and ANCA-negative small-vessel vasculitis from unopposed proteolysis; tender ulcerating plaques or purpura with normal ANCA serology should prompt AAT testing.

• The classic stem: a patient under ~45 with dyspnea, obstruction on spirometry, and little or no smoking history — or a smoker whose disease is far worse than the pack-years predict. Add unexplained transaminase elevation or cirrhosis and the diagnosis is essentially given.
• Single best next step: measure a serum alpha-1 antitrypsin level; if low or borderline, confirm with Pi phenotyping (isoelectric focusing) or SERPINA1 genotyping. Both GOLD and the ATS/ERS statement recommend testing all patients with fixed airflow obstruction, not just the young.
• AAT is an acute-phase reactant: during infection, inflammation, or pregnancy the level can rise into the normal range and mask deficiency. Interpret alongside CRP, or go straight to genotype. This is the most common testing pitfall tested on exams.
• Emphysema pattern: panacinar (panlobular) emphysema with basilar/lower-lobe predominance and bullae — the deliberate contrast with the centriacinar, upper-lobe emphysema of ordinary cigarette smoking. Beware the distractor that reverses these two.
• Liver buzzword: ***PAS-positive, diastase-resistant* eosinophilic globules in periportal hepatocytes** on biopsy — retained polymerized Z protein, not a systemic deficiency phenomenon.
• The mechanism examiners love: unopposed neutrophil elastase degrades elastin; cigarette smoke additionally oxidizes the methionine residue at the reactive site, inactivating residual AAT — a true gene–environment interaction, which is why smoking cessation outranks every drug.
• In a newborn: AATD is a leading genetic cause of neonatal conjugated hyperbilirubinemia and must be distinguished from biliary atresia — the latter needs urgent HIDA/intraoperative cholangiography and Kasai portoenterostomy, so do not stop at the AAT level in an infant with acholic stools.
• Therapy distractors to avoid: IV augmentation therapy helps lung disease only and has no role in AATD liver disease (the liver problem is protein retention, not protease excess); it is also not indicated for asymptomatic individuals with normal spirometry or for MZ heterozygotes. Liver transplantation is curative because the recipient acquires the donor's Pi phenotype.